FDA Approves Jemperli for Certain Patients with Locally Advanced Rectal Cancer
The U.S. Food and Drug Administration has granted accelerated approval for a new indication for the immunotherapy Jemperli (dostarlimab-gxly). The approval covers the use of Jemperli alone in adults with previously untreated stage II or stage III locally advanced rectal cancer whose tumors are mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H).
This approval provides an alternative option that may allow eligible patients to avoid standard treatments like chemotherapy, radiation and surgery, which often carry life-changing effects on daily functioning and fertility. The decision was supported by interim results from clinical trials demonstrating high rates of cancer-free status without the need for additional interventions, though further studies are required to confirm lasting benefits.
Key points
- Jemperli received accelerated approval for untreated stage II or stage III locally advanced rectal cancer.
- Eligible patients must have dMMR or MSI-H tumors confirmed by an authorized test.
- The immunotherapy can be used alone to help certain patients avoid standard chemotherapy, radiation and surgery.
- Common side effects include fatigue, rash, diarrhea and itching, and it can cause severe immune-mediated adverse reactions.
What it means for you
This approval introduces a novel immunotherapy option that may spare eligible patients with dMMR or MSI-H locally advanced rectal cancer from the debilitating effects of traditional surgery, radiation and chemotherapy. Clinicians and pharmacists in Pakistan should check with the Drug Regulatory Authority of Pakistan (DRAP) regarding the local availability and registration status of Jemperli, and consult official prescribing guidelines for patient selection and management of immune-related adverse effects.
FDA Approves Immunotherapy That May Allow Certain Patients with Rectal Cancer to Avoid Chemotherapy, Radiation and Surgery
Summarised automatically from the official announcement. For educational purposes only — check the original source before making clinical decisions.